Hyderabad: Suven Life Sciences Ltd has been granted two product patents, one each from the US and Japan, for its New Chemical Entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and were being developed as therapeutic agents.
“They are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s disease, Attention Deficient Hyperactivity Disorder (ADHD), Huntington’s disease, Parkinson and Schizophrenia.
With these new patents, Suven has 15 granted patents from the US and seven granted patents from Japan. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally,” Venkat Jasti, CEO of Suven, said in a release on Tuesday.
No comments:
Post a Comment